A Prognostic Methylation-Driven Two-Gene Signature in Medulloblastoma.

Area of Science:

• Oncology
• Genetics
• Epigenetics

Background:

• Medulloblastoma (MB) is a common pediatric brain tumor with a significant unmet need for reliable prognostic markers.
• Current prognostic parameters for MB have limited accuracy, challenging clinical management and patient outcomes.

Purpose of the Study:

• To develop and validate a novel gene signature for predicting prognosis in medulloblastoma patients.
• To identify methylation-driven genes (MDGs) as potential biomarkers for MB.

Main Methods:

• Utilized RNA gene expression and DNA methylation data from 1679 primary MB and control samples.
• Employed LASSO regression incorporating MDGs to derive a two-gene signature (GS-2: CEMIP and NCBP3).
• Validated the GS-2 prognostic model using Kaplan-Meier analysis and receiver operating characteristic curves on independent datasets.

Main Results:

• The GS-2 signature demonstrated significant accuracy in predicting overall survival (OS) at 1, 3, and 5 years.
• GS-2 proved to be a robust and independent prognostic biomarker for MB, outperforming traditional markers.
• The methylation-regulated GS-2 risk score effectively classified patients into high- and low-risk groups.

Conclusions:

• The developed GS-2 signature represents a promising, epigenetically-regulated prognostic tool for medulloblastoma.
• This gene signature has the potential to refine risk stratification and guide treatment decisions for pediatric MB patients.
• Highlights the critical role of epigenetic modifications in medulloblastoma pathogenesis and prognosis.